Impax Asset Management Group
CRNX icon

Impax Asset Management Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Impax Asset Management Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
435,000
+85,000
+24% +$3.16M 0.11% 130
2026
Q1 		$12.7M Buy
350,000
+75,000
+27% +$3.35M 0.09% 135
2025
Q4 		$12.8M Buy
+275,000
New +$12.2M 0.08% 132

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impax Asset Management Group's CRNX Position: Q2 2026 in Review

Impax Asset Management Group increased its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q2 2026, buying an estimated $3.16M and bringing the position to 435,000 shares worth $16.3M. The position accounts for 0.11% of the portfolio, ranked #130.

Impax Asset Management Group first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Impax Asset Management Group held 435,000 shares of Crinetics Pharmaceuticals worth $16.3M as of Q2 2026.
  • Impax Asset Management Group bought 85,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.16M.
  • Crinetics Pharmaceuticals made up 0.11% of Impax Asset Management Group's portfolio in Q2 2026, its #130 holding.
  • Impax Asset Management Group first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.